[144] Apellis Pharmaceuticals, Inc. SEC Filing

Rhea-AI Filing Summary

Apellis Pharmaceuticals, Inc. (APLS) Form 144 reports a proposed sale of 548 shares of common stock through Fidelity Brokerage Services LLC with an aggregate market value of $15,386.20. The filing shows approximately 126,289,910 shares outstanding and lists the approximate sale date as 09/02/2025 on the NASDAQ. The shares were acquired by restricted stock vesting on 08/29/2025 and the stated nature of payment is compensation. The filer reports no securities sold in the past three months and includes the standard Rule 144 attestation regarding material nonpublic information.

Insights

Securities Analyst

TL;DR: Insignificant planned sale by a vested holder; small position relative to outstanding shares.

The notice documents a proposed sale of 548 shares valued at $15,386.20 through Fidelity, acquired via restricted stock vesting on 08/29/2025 and slated for sale on 09/02/2025. Against the reported 126,289,910 shares outstanding, the position is immaterial in size. The filing follows standard Rule 144 procedures and contains the customary attestation about material nonpublic information. There are no reported sales in the prior three months.

Corporate Governance Expert

TL;DR: Routine insider transaction disclosure; no governance red flags apparent from this notice alone.

The Form 144 shows the securities were issued as compensation (restricted stock vesting) and the sale will be executed via a broker. The filing includes the required representation regarding material adverse information. The document does not disclose the filer's relationship to the issuer or any trading plan dates. Based solely on the information provided, this is a standard compliance filing without material governance concerns.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	548	15386.20	126289910	09/02/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/29/2025	Restricted Stock Vesting	Issuer			548	08/29/2025	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does Apellis' (APLS) Form 144 report?

The filing reports a proposed sale of 548 common shares acquired by restricted stock vesting, valued at $15,386.20, to be sold via Fidelity on 09/02/2025.

When were the shares acquired and how were they paid for?

The shares were acquired on 08/29/2025 via restricted stock vesting and the stated nature of payment is compensation.

How many Apellis shares are outstanding according to the filing?

The filing lists 126,289,910 shares outstanding.

Were any Apellis securities sold by this person in the past three months?

No; the filing states "Nothing to Report" for securities sold during the past three months.

Which broker is handling the proposed sale in the Form 144?

The broker named is Fidelity Brokerage Services LLC, 900 Salem Street, Smithfield, RI 02917.